Alcohol Laboratory, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Alcohol Alcohol. 2013 Jul-Aug;48(4):478-82. doi: 10.1093/alcalc/agt045. Epub 2013 May 19.
Measurement of an alcohol-induced shift in the serum transferrin glycosylation pattern, termed carbohydrate-deficient transferrin (CDT), is used as a biomarker for sustained high alcohol consumption. The present work examined whether non-enzymatic reaction of transferrin with glucose (glycation) might interfere with the use of CDT as an alcohol biomarker.
The blood specimens were leftover volumes from the routine sample pool. Plasma and serum were collected among samples submitted for hemoglobin A1c (HbA1c) and CDT testing. Quantification of individual transferrin glycoforms in percentage of total transferrin was performed by an HPLC candidate CDT reference method.
Incubating serum spiked with 20 or 200 mmol/l glucose caused time- and dose-dependent changes in the chromatographic profile of transferrin glycoforms, resulting in gradually wider peaks and reduced relative amounts of disialo- and trisialotransferrin. No similar chromatographic effects were seen in samples collected from diabetic patients with elevated HbA1c (>68 mmol/mol) values. These samples instead showed slightly higher mean %disialotransferrin levels (1.21%) compared with low HbA1c (<44 mmol/mol) samples (mean 1.06%; P = 0.023), pointing at a higher alcohol consumption level in the former group. Altogether ∼5% of the CDT values exceeded the cutoff. There was no significant difference in phosphatidylethanol (PEth) levels between the high and low HbA1c samples, but several (∼14%) showed elevated PEth concentrations.
Glycation of serum transferrin in vivo was indicated to differ from that in vitro, and suggested not to interfere with %CDT testing by the HPLC method. The results indicated that CDT and PEth are useful as objective, complementary alcohol biomarkers to identify risky drinking also in diabetic subjects.
测量血清转铁蛋白糖基化模式的酒精诱导变化,称为糖基化不足转铁蛋白(CDT),被用作持续大量饮酒的生物标志物。本研究旨在检查转铁蛋白与葡萄糖的非酶反应(糖化)是否会干扰 CDT 作为酒精生物标志物的使用。
血液标本是常规样本池的剩余量。在提交用于血红蛋白 A1c(HbA1c)和 CDT 测试的样本中收集血浆和血清。通过 HPLC 候选 CDT 参考方法,以转铁蛋白总量的百分比定量测定各转铁蛋白糖型的含量。
在血清中加入 20 或 200mmol/L 葡萄糖孵育会导致转铁蛋白糖型的色谱图谱随时间和剂量发生变化,导致峰逐渐变宽,双涎酸和三涎酸转铁蛋白的相对含量减少。在 HbA1c 值升高(>68mmol/mol)的糖尿病患者的样本中未观察到类似的色谱效应。这些样本的平均 %双涎酸转铁蛋白水平(1.21%)略高于 HbA1c 水平较低(<44mmol/mol)的样本(平均 1.06%;P=0.023),表明前者组的饮酒水平较高。共有约 5%的 CDT 值超过了截止值。高 HbA1c 和低 HbA1c 样本之间的磷脂酰乙醇(PEth)水平没有显著差异,但有几个(约 14%)显示出升高的 PEth 浓度。
体内血清转铁蛋白的糖化作用表明与体外不同,并且不会干扰 HPLC 方法对%CDT 的测试。结果表明,CDT 和 PEth 可作为客观、互补的酒精生物标志物,用于识别糖尿病患者的危险饮酒行为。